PRO GLP + HRT Monitoring Panel
Metabolic, Cardiovascular, and Hormone Monitoring in One At-Home Package
PRO Sports Medicine Learning Center
Introduction
Metabolic health and hormone health are deeply connected. Excess body fat lowers testosterone and SHBG in men and increases conversion of testosterone to estradiol. Insulin resistance changes how hormones are bound and transported. Weight loss often improves hormone levels, and hormone therapy can influence body composition, recovery, and red blood cell production.
Many PRO patients are working on both at the same time: a GLP-1 based weight-management program and testosterone or hormone replacement therapy. The PRO GLP + HRT Monitoring Panel combines the PRO GLP & Cardio Panel with the PRO HRT Monitoring Panel so both treatments can be monitored with one at-home package.
What the Combination Covers
From the GLP & Cardio Panel:
An expanded lipid panel with ApoB, VLDL, and calculated LDL-to-HDL, LDL-to-ApoB, and triglyceride-to-HDL ratios
HbA1c, C-peptide, and estimated average glucose
Liver markers: ALT, AST, GGT, ALP, AST-to-ALT ratio, and direct bilirubin
Kidney markers: creatinine, BUN, BUN-to-creatinine ratio, and eGFR
hsCRP, TSH, and total protein
From the HRT Monitoring Panel:
A complete blood count: hematocrit, hemoglobin, red and white cell counts, platelets, MCV, MCH, MCHC, RDW, and MPV
Total testosterone, free testosterone (calculated), SHBG, albumin, and estradiol
A sex-specific marker: PSA for men or progesterone for women
Each biomarker is explained in the PRO GLP & Cardio Panel and PRO HRT Monitoring Panel chapters.
Why Combine These Two Panels
Two treatments, one monitoring plan. Hormone therapy requires regular checks of hematocrit, hormone levels, and the sex-specific marker: PSA in men, progesterone in women. GLP-1 care benefits from regular checks of glucose regulation, lipids, liver, and kidney function. Combining them avoids duplicate kits and keeps results aligned in time, which makes interpretation easier.
Hydration affects both. GLP-1 medications can reduce fluid intake and cause GI losses, and dehydration can falsely raise hematocrit and affect kidney markers. Seeing the CBC and kidney markers side by side helps a provider recognize when hydration, rather than a true change, is behind an abnormal value.
Weight loss changes hormone results. As body fat falls, SHBG often rises, estradiol may fall, and testosterone may change. A combined panel lets the provider interpret hormone results with the metabolic picture in view, rather than adjusting doses in isolation.
Progesterone for women on HRT. For women, the female configuration measures progesterone, which shows the second half of the hormone balance alongside estradiol. Women on menopausal hormone therapy who have a uterus usually take a progestogen with estrogen to protect the uterine lining, and a progesterone level can help confirm absorption of prescribed progesterone and put symptoms such as sleep or mood changes in context. Synthetic progestins do not show up on a progesterone test, and levels vary with the route of use. In women who still cycle, progesterone rises after ovulation and peaks about a week before the next period, so the cycle day of collection matters. Weight loss can also restore more regular ovulation in some women, which can change progesterone results over the course of a GLP-1 program.
Cardiovascular risk deserves attention on both fronts. Hormone therapy and metabolic disease each have cardiovascular implications. Having ApoB, lipids, hsCRP, and hematocrit on the same report supports a more complete cardiovascular discussion.
A Practical Monitoring Rhythm
A baseline test before either therapy begins is the most valuable single measurement, because it shows what is native to you and what is a treatment effect. Hormone guidelines commonly recommend checking hematocrit and testosterone a few months after starting or changing testosterone therapy and periodically thereafter, while GLP-1 programs commonly recheck HbA1c and lipids after several months of treatment. Lining up those schedules with one combined kit means both therapies are evaluated with data collected on the same day, under the same hydration and training conditions. Your provider sets the exact interval based on your protocols and results.
Who the Panel Is For
Patients using GLP-1 medications such as semaglutide or tirzepatide who are also on TRT or HRT
Patients in a medically supervised weight-loss program considering hormone therapy
Patients who want both hormone health and cardiometabolic progress tracked together
PRO Foundations members who want efficient, comprehensive monitoring
How to Prepare
Follow the kit instructions for each component.
Collect in the morning. If you are on hormone therapy, collect at the point in your dosing cycle your provider specifies, and note the date and time of your last dose.
Fast for 8 to 12 hours unless your provider advises otherwise (water is allowed) for lipid and C-peptide consistency.
Hydrate well in the day before collection. This matters for both hematocrit and kidney markers.
Men should avoid ejaculation and long bike rides for about 48 hours before collection, which can raise PSA.
Women who still have cycles should ask their provider which cycle day to collect for progesterone, and women on progesterone therapy should note the product, route, dose, and time of the last dose.
Avoid heavy training for a day or two, and pause high-dose biotin if your provider agrees.
How Your Results Are Reviewed
A PRO Sports Medicine provider reviews the full report with your GLP-1 and hormone protocols, weight trend, body composition, symptoms, and history. Key questions include whether glucose regulation and lipids are improving, whether liver and kidney markers are stable, whether hematocrit is in a safe range, whether testosterone and estradiol are appropriate for your protocol, and whether PSA (men) or progesterone (women) fits the picture. Treatment changes are made only by your provider. Clinical laboratory review is included for eligible PRO Foundations members; nonmember review services may be available separately.
How It Fits PRO Care
This panel is designed for the overlap between PRO's weight-management and hormone programs. Paired with body composition tracking through PRO Foundations, it helps confirm that fat loss, muscle preservation, metabolic improvement, and safe hormone levels are all moving in the right direction. For background, see Body Composition & Sarcopenia and Cardiovascular Health.
Order the PRO GLP + HRT Monitoring Panel
Important Information
This article is educational and is not medical advice. Results support clinical evaluation and monitoring and do not diagnose medical conditions or replace medical care. Never change a medication or hormone dose based on a lab result without speaking with your provider. All results are reviewed by a licensed PRO Sports Medicine provider.
Key References
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol. Circulation. 2019.
American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes. Diabetes Care (updated annually).
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013.
Clinical Perspective
When patients are on both metabolic and hormone therapy, the two treatments influence each other's lab results. Hydration, body fat, and insulin sensitivity all shift hormone and blood count values. A combined panel collected at a single point in time lets providers see those interactions directly, which reduces the risk of over-adjusting one therapy for a change actually driven by the other.